Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
Beyond the Headlines: Funding Research, Vaccines, Sleep Health, and AI in Healthcare
Beyond the Endpoint
26 minutes 43 seconds
1 month ago
Beyond the Headlines: Funding Research, Vaccines, Sleep Health, and AI in Healthcare
The "Beyond the Headlines" series returns with summer healthcare and research news. Hosts Manesh Patel and Emily O'Brien discuss misconceptions about research funding, a Danish study on vaccine safety, the potential impacts of poor sleep, and how AI tools are transforming medical practice and training.
Tags: #medicalnews #healthnews #research #clinicalresearch
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
